KRAS and lung carcinoma: Finally, Aurora kinase pharmacological inhibition preferentially targets lung cancer cells expressing KRASG12V, thereby supporting our hypothesis that AURKA and AURKB are promising targets for KRAS-induced lung cancer therapy.